How to Get Belsomra (Suvorexant) in Washington State

What Is Suvorexant and Why Does It Matter for Insomnia?

Suvorexant is a dual orexin receptor antagonist (DORA) that blocks wakefulness-promoting neuropeptides orexin-A and orexin-B. Unlike benzodiazepines or Z-drugs that broadly suppress central nervous system activity, suvorexant targets the specific arousal pathway driving wakefulness. The FDA approved Belsomra in August 2014 for adults with insomnia characterized by difficulty with sleep onset, sleep maintenance, or both 1.

In the key phase III trial by Herring et al. (2014, N=3,291 across two studies), suvorexant at 40 mg and 20 mg significantly improved subjective total sleep time (sTST) and reduced subjective time to sleep onset (sTSO) compared with placebo over 3 months. The 20 mg dose increased sTST by approximately 22 minutes compared with placebo at month 1 2. These were durable effects. Patients maintained improvements through month 3 without evidence of rebound insomnia upon discontinuation.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline conditionally recommends suvorexant for sleep maintenance insomnia, citing moderate-quality evidence from randomized controlled trials 3. For Washington residents seeking an alternative to older sedative-hypnotics, suvorexant offers a mechanistically distinct option with a lower risk profile for respiratory depression and dependence.

Washington State Telehealth Rules for Belsomra Prescriptions

Washington fully permits telehealth prescribing for Schedule IV controlled substances, including suvorexant. A prescriber can evaluate a patient via synchronous audio-video visit, establish a provider-patient relationship, and issue an electronic prescription to any Washington pharmacy. This is legal under Washington's Revised Code (RCW 18.130.250) and aligns with DEA telehealth flexibilities extended through 2025 and currently proposed for permanent adoption 4.

The practical workflow is straightforward. A patient completes a medical intake, including sleep history, current medications, and screening for contraindications such as narcolepsy. The prescriber conducts a live video consultation, reviews the patient's history, and determines whether suvorexant is appropriate. If so, the prescription is sent electronically to the patient's preferred Washington pharmacy. No in-person visit is required for the initial prescription.

HealthRX and similar telehealth platforms operating in Washington hold appropriate state licenses and employ providers credentialed in the state. Washington is one of 14 states where nurse practitioners hold full independent prescriptive authority, meaning NPs can prescribe Belsomra without physician oversight 5. This broadens access, particularly in rural counties east of the Cascades where sleep medicine specialists are scarce.

Who Can Prescribe Belsomra in Washington?

Any Washington-licensed prescriber with a valid DEA registration and Schedule IV authority can prescribe suvorexant. This includes physicians (MDs and DOs), nurse practitioners, and physician assistants.

Washington grants NPs full practice authority under RCW 18.79.250, removing the collaborative agreement requirement that exists in many other states. PAs in Washington prescribe under a practice agreement with a supervising physician, but this agreement can explicitly include Schedule IV medications. A PA whose practice agreement covers controlled substances can write a Belsomra prescription independently during a clinical encounter.

Sleep medicine board certification is not required. Primary care providers prescribe the vast majority of insomnia medications nationally. A 2019 analysis published in the Journal of Clinical Sleep Medicine found that primary care clinicians wrote 79% of all hypnotic prescriptions in the United States 6. Patients do not need a specialist referral to obtain suvorexant in Washington unless their insurance plan requires one for coverage purposes.

For complex cases involving comorbid obstructive sleep apnea, a referral to a board-certified sleep medicine physician may be clinically appropriate. Suvorexant does not carry the same respiratory suppression risk as benzodiazepine receptor agonists, but the Herring et al. trial excluded patients with severe untreated sleep apnea (AHI >15), so clinicians typically want apnea ruled out or adequately treated before prescribing 2.

Labs and Clinical Evaluation Before Starting Suvorexant

Suvorexant does not require routine laboratory monitoring before initiation or during ongoing therapy. No hepatic function panels, renal function tests, or blood level monitoring are part of the standard prescribing protocol.

The required clinical evaluation focuses on three areas. First, a thorough sleep history: onset patterns, maintenance difficulties, duration of symptoms (insomnia disorder requires symptoms at least 3 nights per week for at least 3 months per ICSD-3 criteria), and impact on daytime function 7. Second, a medication reconciliation to identify CYP3A4 inhibitors. Suvorexant is primarily metabolized by CYP3A4, and concurrent use of strong CYP3A4 inhibitors such as ketoconazole, itraconazole, clarithromycin, or ritonavir is contraindicated. The FDA label recommends a dose reduction to 5 mg when moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, fluconazole) are used concurrently 1. Third, screening for narcolepsy. Because suvorexant blocks orexin signaling, giving it to a patient with narcolepsy (a condition already marked by orexin deficiency) could worsen cataplexy and excessive daytime sleepiness.

Optional but sometimes useful: an overnight polysomnography or home sleep apnea test if obstructive sleep apnea is suspected. Some Washington insurers require a sleep study before authorizing any hypnotic, though this is more common for commercial plans than Medicaid.

Washington Medicaid Coverage and Prior Authorization

Washington Apple Health (Medicaid) covers suvorexant with prior authorization. The state's Preferred Drug List, managed by the Washington Health Care Authority (HCA), classifies DORAs as non-preferred agents, meaning a prescriber must submit documentation before the pharmacy can fill the prescription under Medicaid.

The prior authorization process requires three elements:

1. Diagnosis confirmation. A documented diagnosis of insomnia disorder (ICD-10 codes G47.00 or G47.09).
2. Step therapy documentation. Evidence that the patient tried and failed, or has a contraindication to, at least one preferred agent. Washington HCA's current preferred list for insomnia includes generic zolpidem, generic trazodone, and generic doxepin (low-dose). "Failure" typically means inadequate response after a 2-to-4-week trial or intolerable side effects.
3. Clinical rationale. A brief statement explaining why suvorexant is medically necessary for this patient. Common justifications include fall risk concerns with Z-drugs in older adults, history of substance use disorder making GABAergic agents inappropriate, or paradoxical reactions to first-line therapies.

Turnaround time for Washington Medicaid PA decisions is typically 24 to 48 hours for standard requests. Urgent requests receive a response within 24 hours per federal Medicaid regulations.

Commercial insurers in Washington follow variable formulary positions. Premera Blue Cross, Regence, Kaiser Permanente of Washington, and Molina all maintain suvorexant on their formularies, though tier placement and PA requirements differ. Patients should verify their specific plan's requirements through their insurer's formulary lookup tool or by calling the member services number on their insurance card.

Pharmacy Access: Retail and 503A Compounding in Washington

Suvorexant is available at all major retail pharmacy chains operating in Washington, including Walgreens, CVS, Rite Aid, Costco, and Walmart. Independent pharmacies also stock or can order the medication within 1 to 2 business days.

Washington licenses 503A compounding pharmacies under the Washington State Department of Health Pharmacy Quality Assurance Commission. These pharmacies can compound suvorexant into alternative formulations (such as oral suspensions for patients who cannot swallow tablets) when a prescriber writes a patient-specific prescription. A 503A pharmacy cannot compound copies of commercially available products unless there is a documented clinical need for a modified formulation.

Pricing without insurance varies significantly. Brand-name Belsomra carries a retail price of approximately $400 to $480 for a 30-tablet supply. Merck offers a manufacturer savings card that can reduce out-of-pocket costs to as low as $40 per fill for commercially insured patients. Generic suvorexant, approved by the FDA in 2023, has brought cash prices down to approximately $50 to $120 for a 30-day supply at most Washington pharmacies. GoodRx and similar discount programs can further reduce the generic price. Patients using Washington Medicaid with an approved PA typically pay $0 to $3 per fill.

Mail-order pharmacy is another option. Express Scripts, OptumRx, and CVS Caremark all include suvorexant in their mail-order catalogs, often at a lower per-unit cost for 90-day supplies.

Transferring a Belsomra Prescription to Washington

Patients relocating to Washington or visiting from another state can transfer an existing suvorexant prescription to a Washington pharmacy. Because suvorexant is a Schedule IV controlled substance, federal law permits transfer of the original prescription between pharmacies, provided the prescription has remaining refills.

The process requires the receiving Washington pharmacy to contact the originating pharmacy directly. The pharmacist at the receiving location verifies the prescription details, remaining refills, prescriber information, and DEA number. Washington pharmacies accept electronic transfers for controlled substances through shared pharmacy systems (e.g., within the same chain) and phone-based transfers between independent pharmacies.

If the original prescription has no remaining refills, the patient will need a new prescription from a Washington-licensed prescriber. A telehealth visit with a Washington-credentialed provider can generate a new electronic prescription, typically within 24 to 48 hours of the consultation.

Washington participates in the Prescription Drug Monitoring Program (PDMP), and dispensing pharmacists are required to check the PDMP before filling Schedule II through IV medications. This is standard and should not delay the transfer process for patients with a legitimate prescription history.

Clinical Considerations: Dosing, Safety, and Duration

The recommended starting dose of suvorexant is 10 mg taken within 30 minutes of bedtime, with at least 7 hours of intended sleep remaining. The dose may be increased to 20 mg if 10 mg is well-tolerated but insufficiently effective. The 5 mg dose is reserved for patients on moderate CYP3A4 inhibitors or those who are sensitive to lower doses 1.

The most common adverse effects in clinical trials were somnolence (7% vs. 3% placebo at the 20 mg dose) and headache. Next-morning drowsiness occurred in a dose-dependent fashion. The FDA specifically warns against driving or operating heavy machinery the morning after taking suvorexant, particularly at the 20 mg dose, based on next-day driving simulation studies 8.

Suvorexant showed no statistically significant withdrawal effects in the Herring et al. trial. Rebound insomnia was assessed at discontinuation and was not observed at rates higher than placebo 2. This contrasts with Z-drugs and benzodiazepines, where rebound insomnia is a recognized phenomenon.

A 2020 meta-analysis by Kishi et al. (N=6,206 across 10 RCTs of all DORAs) confirmed that orexin receptor antagonists improve sleep onset latency and total sleep time with a number needed to treat (NNT) of 8 for a clinically meaningful response, defined as a Patient Global Impression of Improvement score of "much improved" or better 9.

Duration of therapy is individualized. The AASM recommends reassessing the need for pharmacotherapy every 4 to 8 weeks and attempting dose reduction or discontinuation when insomnia symptoms have been stable for at least 3 months with concurrent behavioral interventions 3.

Suvorexant Compared with Other Washington-Available Insomnia Medications

Washington residents have access to the full range of FDA-approved insomnia pharmacotherapies. Understanding where suvorexant fits helps patients and prescribers make informed choices.

Zolpidem (generic Ambien) remains the most prescribed insomnia medication nationally and is the first-line pharmacologic option on most Washington formularies. It is inexpensive (generic: $5 to $15 per month) and effective for sleep onset, but it carries higher risks for complex sleep behaviors (sleep-driving, sleep-eating) and next-morning impairment, particularly in women and older adults. The FDA issued a black-box warning for eszopiclone, zaleplon, and zolpidem in 2019 regarding serious injuries from complex sleep behaviors 10.

Lemborexant (Dayvigo), a second DORA, gained FDA approval in December 2019 and is available at Washington pharmacies. The SUNRISE-2 trial (N=949) compared lemborexant 5 mg and 10 mg against placebo over 12 months, demonstrating sustained efficacy in sleep onset and maintenance 11. Head-to-head data between suvorexant and lemborexant are limited to indirect comparisons; both agents target the same receptor system with similar clinical profiles.

Low-dose doxepin (Silenor, 3 mg and 6 mg) is effective for sleep maintenance but has minimal effect on sleep onset latency, making it less suitable for patients with both onset and maintenance difficulties.

Cognitive behavioral therapy for insomnia (CBT-I) remains the recommended first-line treatment per the American College of Physicians (ACP) 2016 guideline 12. Pharmacotherapy, including suvorexant, is most appropriately used when CBT-I alone is insufficient or as a bridge while CBT-I skills are being developed. Several Washington-based providers offer CBT-I via telehealth, and it can be combined with suvorexant therapy.

Timeline: From Consultation to First Dose

The typical process for a Washington resident obtaining suvorexant through telehealth follows a predictable sequence.

Day 1. Complete online intake and schedule a synchronous video visit with a Washington-licensed prescriber. Some platforms offer same-day appointments.

Day 1 to 2. Prescriber conducts evaluation, determines appropriateness, and sends an e-prescription to the patient's chosen Washington pharmacy.

Day 2 to 5. If no prior authorization is required (commercial plan with suvorexant on formulary, or cash pay), the pharmacy dispenses within 24 to 48 hours. If PA is needed, the prescriber's office submits the request; Washington Medicaid responds within 24 to 48 hours.

Day 3 to 7. Patient picks up or receives medication via mail-order pharmacy.

Total elapsed time: 3 to 7 business days for most patients. Patients paying cash without insurance can often obtain the medication within 2 to 3 days, since no PA step is involved.